Latest Hotspot

CDR-Life Begins Phase 1 Trial of CDR404 for Solid Tumors at ASCO

3 June 2024
3 min read

CDR-Life Inc. has started enrolling participants for the Phase 1 clinical trial of CDR404, their leading candidate being developed as a targeted immunotherapy for the treatment of solid tumors. An abstract about CDR404 has been approved for online presentation at the 2024 American Society of Clinical Oncology Annual Meeting, scheduled to take place from June 3 to June 4 in Chicago, Illinois.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 应用程序

描述已自动生成

Leveraging its proprietary M-gager® technology, CDR404 stands out as an innovative, antibody-based bivalent and bispecific MAGE-A4 T-cell engager designed to treat MAGE-A4 positive solid tumors. 

"We are delighted with the advancements achieved following the approval of our Investigational New Drug application by the U.S. FDA earlier this year, along with the subsequent authorization of the Clinical Trial Application in Denmark. We look forward to sustaining this positive momentum," remarked Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. "This significant milestone brings us closer to our objective of providing a superior off-the-shelf therapy for cancer patients in critical need."

The ASCO abstract outlines findings from a study evaluating the biomarkers that predict the efficacy of CDR404 against non-small cell lung cancer tumors.

CDR-404 precisely targets HLA and MAGEA4 and is aimed at treating various conditions, including neoplasms, digestive system disorders, respiratory diseases, and urogenital diseases. The targeted indications for CDR-404 encompass advanced malignant solid neoplasm, bladder cancer, esophageal carcinoma, and lung cancer. According to the most recent data, CDR-404 is currently in Phase 1 of clinical trials.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of June 3, 2024, there are 3 investigational drugs for the HLA and MAGEA4 targets, including 8 indications, 2 R&D institutions involved, with related clinical trials reaching 1, and as many as 1175 patents.

CDR-404 represents a significant advancement in the field of biomedicine, particularly in the area of cancer treatment. The drug's bispecific antibody design, coupled with its targeting of multiple therapeutic areas and active indications, positions it as a potential candidate for addressing unmet medical needs in the treatment of various cancers and related disorders. Further clinical development and evaluation will be necessary to determine the full potential of CDR-404 in improving patient outcomes in these disease areas.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

LIB Therapeutics Reveals Positive Phase 3 Lerodalcibep Data at EAS Congress
Latest Hotspot
3 min read
LIB Therapeutics Reveals Positive Phase 3 Lerodalcibep Data at EAS Congress
3 June 2024
LIB Therapeutics Shares Positive Phase 3 Lerodalcibep Results at 92nd European Atherosclerosis Society Congress.
Read →
Atara Biotherapeutics Presents Early CAR T Therapy Research on CD19 at ISCT 2024
Latest Hotspot
3 min read
Atara Biotherapeutics Presents Early CAR T Therapy Research on CD19 at ISCT 2024
3 June 2024
Atara Biotherapeutics Presents Early Research on ATA3219, a CAR T Therapy Targeting CD19 for B-Cell Autoimmune Diseases, at ISCT 2024.
Read →
Bio-Thera and STADA Sign Exclusive Deal for Golimumab Biosimilar in Europe and UK
Latest Hotspot
3 min read
Bio-Thera and STADA Sign Exclusive Deal for Golimumab Biosimilar in Europe and UK
3 June 2024
The partnership involves the commercialization and licensing of BAT2506, a biosimilar of Simponi® (golimumab).
Read →
Outlook Therapeutics Gains EU Approval for Wet AMD Drug LYTENAVA™
Latest Hotspot
3 min read
Outlook Therapeutics Gains EU Approval for Wet AMD Drug LYTENAVA™
31 May 2024
Outlook Therapeutics® Gains European Commission Approval for Marketing LYTENAVA™ (bevacizumab gamma) to Treat Wet AMD.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.